MARKET WIRETradingView • 22h ago
electroCore, Inc. Estimates – NASDAQ:ECORTradingView report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
Why ECOR Stock dropped -4.79% Today — RQD Quant Desk Flash
$7.16 -4.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.08
electroCore Inc. (ECOR) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $67.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ECOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ECOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, electroCore Inc. (NASDAQ: ECOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.16 (-4.79% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ECOR ranks #839 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ECOR compare to OM and HYPR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ECOR?
▼
Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.08 (-1.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ECOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY ECOR SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (38% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 86.8% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$8.39-10.7% Next Q
37
Q2 (-2Q)Grade E$7.49+3.6% Next Q
34
Q3 (-1Q)Grade E$7.76-7.7% Next Q
32
CurrentGrade E$7.16-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ECOR Turnaround Squeeze
While ECOR currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.40) and Max Pain ($7.52) forces dealer call-delta covering toward $13.33.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ECOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ECOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ECOR Stock dropped -4.79% Today — RQD Quant Desk Flash
electroCore Inc. (ECOR) dropped -4.79% to $7.16, trading at 33% of its 52-week range ($4.41 – $12.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 33% of its 52-week range ($4.41 – $12.7) with RSI-14 at 39.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.16 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 86.8% gross margin and $0 annual free cash flow.
Live ECOR Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 1d ago
electroCore, Inc. (ECOR) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
When Can We Expect A Profit From electroCore, Inc. (NASDAQ:ECOR)?Simply Wall St report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Across two studies, chemo-related nerve pain scores fell about 40% in Quell's active treatment group.Stock Titan report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
electroCore (ECOR) Files FDA 510(k) for Quell Device Targeting CGuruFocus report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026Yahoo Finance report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com UK • 1d ago
electroCore at Planet MicroCap Showcase: Toronto 2026: growth broadens By Investing.comInvesting.com UK report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMugglehead Investment Magazine • 1d ago
electroCore seeks FDA clearance for Quell in chemotherapy neuropathyMugglehead Investment Magazine report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 14h ago
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesNeurocrine (NBIX) delivered earnings and revenue surprises of +29.53% and +8.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
CATALYSTYahoo • 5d ago
electroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities ExpandJoshua Lev, co-CEO, president and CFO of electroCore (NASDAQ:ECOR), said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand product indications and re
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ECOR)
- ✓Walkthrough of ECOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ECOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.19%🛡️ HOLDING TREND SUPPORT
2026-11-03O $8.11H $8.11L $7.16C $7.16VOL 65.8K
RES: $13.60SUP: $7.15SMA50: $9.40SMA200: $7.75
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ECOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +27.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ECOR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ECOR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ECOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ECOR)
Health Care Rank #839 of 1015
⚔️ OM vs ECOR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ECOR vs. OM, HYPR, STXS, NRXS)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, electroCore Inc. (ECOR) ranks #839 by composite RQD confidence (29/100, grade E) and #704 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, ECOR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ECOR at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ECOR
ACTIVE
electroCore Inc. | E | 29/100 | — | 86.8% | -35.0% | -4.79% | $67.8M | Benchmark Subject |
| OM Outset Medical Inc. | E | 34/100 | — | 39.1% | -28.0% | -0.25% | $75.8M | /om-vs-ecor → |
| HYPR Hyperfine Inc. (Class A) | D- | 38/100 | — | 49.8% | -35.0% | +0.99% | $76.1M | /hypr-vs-ecor → |
| STXS Stereotaxis Inc. | E | 22/100 | — | 52.7% | -35.0% | +2.03% | $86.4M | /stxs-vs-ecor → |
| NRXS Neuraxis Inc. | D- | 36/100 | — | 84.2% | -35.0% | -7.43% | $89.5M | /nrxs-vs-ecor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560258 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), electroCore Inc. (ECOR) reported GAAP revenue of $32.0M (+27.2% vs. FY2024 revenue of $25.2M , and +99.8% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$8.2M, and free cash flow of -$8.3M (-18.8% YoY). On the balance sheet, ECOR closed FY2025 with $18.7M in total assets against $6.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $32.0M | -$14.0M | -$8.2M | -$8.3M | $18.7M | $6.6M |
| FY2024 (FY) | 2024-12-31 | $25.2M | -$11.9M | -$6.9M | -$6.9M | $20.5M | — |
| FY2023 (FY) | 2023-12-31 | $16.0M | -$18.8M | -$14.7M | -$14.7M | — | — |
3. ECOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ECOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, electroCore Inc. (NASDAQ: ECOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.16 (-4.79% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ECOR ranks #839 in composite RQD confidence.
How does ECOR compare to OM and HYPR in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ECOR?
Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ECOR trading relative to its 50-day, 200-day, and 52-week technical levels?
ECOR last traded at $7.16 (-4.79% on volume of 94,139 shares), positioning the stock -23.83% below its 50-day simple moving average ($9.40) and -7.61% below its 200-day simple moving average ($7.75). Across its 52-week range of $4.41 to $12.70, ECOR sits at the 33.2% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.26 to $8.06).
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ SEC XBRL & RQD VERIFIED
ECOR — electroCore Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
electroCore Inc. (ECOR) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.16 (-4.79% 1D, market capitalization $67.8M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 86.8%, operating margin of -41.1%, and free cash flow yield of -11.29%.
- Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (3/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
ElectroCore Inc. (ECOR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The market capitalization is $0.1B. The company reported FY 2025 revenue of $32.0M, up from $25.2M in FY 2024 and $16.0M in FY 2023.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), electroCore Inc. (ECOR) reported $32.0M in annual revenue (up from $25.2M in FY2024, +27.2% YoY) and -$14.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($16.0M revenue, -$18.8M net income) through FY2025, ECOR scaled operating cash flow to -$8.2M and free cash flow to -$8.3M, backed by $18.7M in total assets against $6.6M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.29% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $4.41 – $12.70 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -41.1% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. A prospective investor should note that the absence of mapped links means the second-order effects of device regulation, reimbursement, or component supply cannot be traced from the provided data. The watch point is the 510(k) and Quell program outcome referenced in the news, since a regulatory or commercial result there would be the most likely first-order event with ripple potential.
- Key Question #1: Can ECOR sustain or expand its -41.1% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $32.0M and free cash flow of -$8.3M, how will capital allocation balance growth reinvestment against $6.6M in total debt?
- Key Question #3: How sensitive is ECOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ECOR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for electroCore Inc. (ECOR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 22h ago
electroCore, Inc. Estimates – NASDAQ:ECOR TradingView report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
electroCore, Inc. (ECOR) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
When Can We Expect A Profit From electroCore, Inc. (NASDAQ:ECOR)? Simply Wall St report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Across two studies, chemo-related nerve pain scores fell about 40% in Quell's active treatment group. Stock Titan report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
electroCore (ECOR) Files FDA 510(k) for Quell Device Targeting C GuruFocus report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 Yahoo Finance report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com UK • 1d ago
electroCore at Planet MicroCap Showcase: Toronto 2026: growth broadens By Investing.com Investing.com UK report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago
electroCore seeks FDA clearance for Quell in chemotherapy neuropathy Mugglehead Investment Magazine report covering electroCore Inc. (ECOR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ECOR Bull vs. Bear Conversation Board — What's Your Call at $7.16?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ECOR 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $9.48 (+26.1%)
📌 Pinned Debate Revenue grew from $16.0M in FY 2023 to $32.0M in FY 2025 while gross margin stands at 86.8%.
Long ECOR at $7.52 targeting $9.48. Revenue grew from $16.0M in FY 2023 to $32.0M in FY 2025 while gross margin stands at 86.8%.. Institutional whale score is 5/20 and the risk/reward vs. the $4.41 52-week low is skewed heavily in favor of bulls.
EarningsSniper 🐂 BULL
Both sides have a point here — ECOR's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $5.87 (-21.9%)
Spot @ $7.52 Free cash flow was -$8.3M in FY 2025 against $7.0M of cash, with ROIC at -35% and FCF yield at -11.29%.
Here is the bear case nobody on the bull side wants to address on ECOR: Free cash flow was -$8.3M in FY 2025 against $7.0M of cash, with ROIC at -35% and FCF yield at -11.29%.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.